List of Omnaris drug patents

Omnaris is owned by Covis.

Omnaris contains Ciclesonide.

Omnaris has a total of 1 drug patent out of which 0 drug patents have expired.

Omnaris was authorised for market use on 20 October, 2006.

Omnaris is available in spray, metered;nasal dosage forms.

Omnaris can be used as treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. treatment of nasal symptoms associated w perennial allergic rhinitis in adults and adolescents 12 years of age and older.

The generics of Omnaris are possible to be released after 01 February, 2028.

OMNARIS's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8371292 COVIS Use of ciclesonide for the treatment of respiratory diseases
Feb, 2028

(4 years from now)

Drugs and Companies using CICLESONIDE ingredient

Market Authorisation Date: 20 October, 2006

Treatment: Treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. treatment of nasal symptoms associated w perennial allergic rhinitis in adults and adolescents 12 years of age and older

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of OMNARIS before it's patent expiration?
More Information on Dosage

OMNARIS family patents

6

United States

2

Japan

2

European Union

1

Portugal

1

Slovenia

1

Croatia

1

Poland

1

Australia

1

Denmark

1

Canada

1

Spain

1

Cyprus

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in